BLACK WEEKSViaalid −15% · komplektid −10% · muu −5%koodigaTasuta tarne Saksamaal alates €200

See leht on tõlgitud automaatselt ja võib sisaldada vigu. Kas eesti keel on sinu emakeel? Ootame hea meelega sinu tagasisidet ja parandusi.Saada tagasisidet

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), toote foto

Laboriaruanne

PDF
Testitud
Testitud
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Labor
Analiza Białek
Kuupäev
October 2026
Tulemus
20.34 mg per tablet (20 mg label)
Tellimuse nr
Parool

Sõltumatult testitud, kontrollitav parooliga otse laboris.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Tellimus

Ühiku hind - Black Weeksi ajal tasuta tarne Saksamaal alates 200 €
  • DHL koos jälgimisega
  • Diskreetne pakend

4.6 5-st Trustpilotis73 arvustust

Lühidalt

Tamoxifen (Nolvadex) arvudes

Põhinäitajad meie leksikonist.

Täielik leksikoni artikkel
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Teadmised

Kõik teemal Tamoxifen (Nolvadex)

FAQ

Korduma kippuvad küsimused

Allikad iga vastuse juurde: leksikoni artikkel

Kas sul on veel küsimusi?

Kirjuta meile, meie meeskond aitab sind.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Võrdlused

Kuidas see võrdub

Seotud

Seotud tooted